|

Poly (ADP-Ribose) Polymerase Inhibitor Clinical Trials

1 actively recruiting trial across 1 location

Also known as: PARP Inhibitor, Poly(ADP-Ribose) Polymerase Inhibitor

Pipeline

Phase 1/2: 1

Top Sponsors

  • University of Washington1

Indications

  • Metastatic Breast Carcinoma1
  • Anatomic Stage IV Breast Cancer AJCC v81
  • Breast Cancer1
  • Cancer1

Seattle, Washington1 trial

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.